摘要Background Steroid-sensitive nephrotic syndrome is a prevalent glomerular disease in children.The 2021 guidelines for glomerular disease management by Kidney Disease:Improving Global Outcomes and the 2023 recommendations for steroid-sensitive nephrotic syndrome management by International Pediatric Nephrology Association recommend rituximab for frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome in children.However,there is consid-erable variation in rituximab application,including administration timing,dose,frequency,concomitant medications,and follow-up schedules.In addition,rituximab use for nephrotic syndrome remains off-label in most countries.Data sources The"Pediatric Nephrology Committee of the Chinese Medical Doctor Association",the"Pediatric Nephrology Society of the Chinese Medical Association",and the"Fudan University GRADE Center"collaborated to develop a clini-cal practice guideline for rituximab in pediatric steroid-sensitive nephrotic syndrome.Databases and starting/ending time for retrieval were as follows.Databases in English:PubMed,Embase,Cochrane,and Scopus;database in Chinese:Chinese Biomedical Literature Service provided by SinoMed.The publication dates were limited to those from 2004 to June 26,2022.Results Through systematic reviews and meta-analyses covering nine clinically relevant patient or population covered,intervention,comparator,and outcome questions,seven recommendations were formulated and formally graded according to these guidelines.Conclusions This guideline aspires to serve as a pivotal resource for healthcare providers,offering guidance on administra-tion timing,dosage,frequency,concomitant medications,and follow-up protocols.